Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Issue Brief
The Relationship Between GLP-1 Use and Trust in Pharmaceutical Companies
Featured Experts: Wändi Bruine de Bruin, Alison Sexton Ward, Dana Goldman
In The News View All
CalMatters
Ward discusses tension between GLP-1 long-term savings and near-term insurer costs
Featured Experts: Alison Sexton Ward
Axios
A recent historic drop in drug prices is largely driven by market forces, Joyce explains
Featured Experts: Geoffrey Joyce
Healthcare Brew
Despite recent reforms, Joyce says PBMs may simply adapt business practices to generate revenue
Featured Experts: Geoffrey Joyce
Pink Sheet
Chen warns MFN could have unintended consequences and highlights need for US value-based pricing
Featured Experts: Alice Chen
MinnPost
Mulligan explains how 340B program encourages hospitals to favor more expensive drugs
Featured Experts: Karen Mulligan
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
